EyePoint, Inc. (EYPT)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jay S. Duker M.D.
|
President, CEO & Director | 1.35M | -- | 1959 |
|
Mr. George O. Elston CPA
|
Executive VP & CFO | 904.8k | -- | 1965 |
|
Dr. Ramiro Ribeiro M.D., Ph.D.
|
Chief Medical Officer | 888.56k | -- | 1983 |
|
Dr. Marcia Sellos-Moura Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Mr. Ron I. Honig Esq.
|
Chief Legal Officer & Company Secretary | -- | -- | -- |
|
Ms. Jennifer Leonard
|
Chief People Officer & Senior VP of IT | -- | -- | -- |
|
Mr. David Scott Jones M.A.
|
Senior Vice President | 672.08k | -- | 1968 |
|
Ms. Isabelle Lefebvre
|
Chief Regulatory Officer | -- | -- | -- |
|
Mr. Michael J. Maciocio
|
Chief Manufacturing Officer | -- | -- | -- |
|
Mr. Michael Campbell
|
Chief Commercial Officer | -- | -- | -- |
EyePoint, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 214
Description
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
November 4, 2026 at 1:30 PM UTC
EyePoint, Inc. Earnings Date
